CDC director files to sell her entire Butterfly (BFLY) stake one day after the 22% pop
Erica Schwartz's Form 144 covers all 401,699 shares she reported owning, marked at $10, the morning after Needham's initiation sent the stock up 22%. The CEO's sales were automatic or pre-scheduled, and he still holds 7.35 million shares.
Vincent Jiangthree-minute read
The director who left for the CDC is selling everything on record
Erica Schwartz stepped off Butterfly Network's−8.55% — Butterfly Network, down 8.55 percent today board on 5 August 2026, the day the Senate confirmed her to run the CDC 45. On 22 September, the day a Buy initiation sent the stock up 21.99% to $9.93 310, she sold 78,679 Class A shares for $786,790 1. The next morning her Form 144 reached EDGAR: 323,020 more shares, aggregate market value $3,230,200 1.
Her most recent ownership filing, from 22 June, reported 401,699 shares 9. The completed sale plus the pending block equals that position exactly. Rule 144 asks no reason, and none is given 1.
The bull case is 2030 money with nothing shipped
Needham's David Saxon opened at Buy with a $10 target, a sum-of-the-parts at roughly 16 times the firm's 2027 sales estimate 3. The model carries an estimated $300 million of Midjourney licensing revenue at 2030 and about $25 million from Mendaera, and concedes no Embedded partnership has launched a commercial product; roughly two-thirds of sales are still the legacy probe business 3. Sixteen times sales across 244.9 million shares implies about $150 million of 2027 revenue, a third more than the trailing four quarters delivered 111.
Affiliates put 685,000 shares on the tape
President, CEO and chairman Joseph DeVivo disclosed $2.07 million of July and August sales, then filed a fresh 2,811-share notice the afternoon of the pop 2. Counting Schwartz's 401,699 shares, disclosed affiliate supply since July runs to about 685,000 shares, 0.28 percent of the 244,858,246 outstanding 12. Small against the float. The signal is who sold, and when.
Butterfly insider blocks grew into the pop, and the biggest is still pending
- Gross proceeds ($M)
- Estimate
Data
| Gross proceeds ($M) | |
|---|---|
| DeVivo, 20 Jul | $1.39M |
| DeVivo, 10 Aug | $0.68M |
| Schwartz, 22 Sep | $0.79M |
| Schwartz, 23 Sep (planned) (estimate) | $3.23M |
The biggest block is the one still pending
Schwartz's 22 September sale printed near $9.99 a share, within half a percent of the $10.05 52-week high 110. The pending block is marked at exactly $10. Her notice lists five vesting tranches running back to June 2024 and no Rule 10b5-1 plan date; DeVivo's carries one, adopted 12 December 2025 12. The bull case is priced in 2030 dollars; the insider paper cleared at $10.
The counter-read: the CEO is staying
DeVivo's July sale of 211,798 shares at an average $6.56 was a sell-to-cover for RSU taxes, automatic and not at his discretion, his Form 4 states 7. The August block ran under the December plan, adopted long before the run 8. He still held 7,353,700 shares after gifting 250,000 to trusts for his children, about $69 million at Wednesday's $9.42 close 63. Buyers met the tape too: 33 hedge funds held $425 million of the stock at the end of June, up from $171 million a quarter earlier 10.
What settles it
Earnings are due around 30 October, guided to $26 to $30 million of revenue and adjusted EBITDA between negative $9 million and negative $6 million 10. Butterfly has lost money in each of the last eight quarters while cash fell to $124.7 million at midyear 11. The tells are the first commercial Embedded shipment, and the Form 4 that follows her last 323,020 shares out the door.
Revenue is growing, but Butterfly has lost money for ten straight quarters
- Revenue ($M)
- Net income ($M)
Data
| Revenue ($M) | Net income ($M) | |
|---|---|---|
| Q1 '24 | $17.66M | -$21.76M |
| Q2 '24 | $21.49M | -$15.71M |
| Q3 '24 | $20.56M | -$16.92M |
| Q4 '24 | $22.35M | -$18.1M |
| Q1 '25 | $21.23M | -$13.97M |
| Q2 '25 | $23.38M | -$13.83M |
| Q3 '25 | $21.49M | -$33.97M |
| Q4 '25 | $31.51M | -$15.29M |
| Q1 '26 | $26.53M | -$12.68M |
| Q2 '26 | $32.61M | -$12.91M |
Get Health by email, free
AI in medicine, pharma and biotech. In our daily email, every weekday.







Reader comments
0 comments